Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers
Open Access
- 15 January 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (1) , 205
Abstract
The humoral response through neutralizing antibodies (NAbs) is a key component of the immune response to COVID-19. However, the plaque reduction neutralization test (PRNT), the gold standard for determining NAbs, is technically demanding, time-consuming and requires BSL-3 conditions. Correlating the NAbs and total antibodies levels, assessed by generalized and automated serological tests, is crucial. Through a commercial surrogate virus neutralization test (sVNT), we aimed to evaluate the production of SARS-CoV-2 NAbs in a set of vaccinated healthcare workers and to correlate these NAbs with the SARS-CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. We found that 6 months after vaccination, only 74% maintain NAbs for the Wuhan strain/UK variant (V1) and 47% maintain NAbs for the South African and Brazil variants (V2). Through Spearman’s correlation, we found the following correlations between the percentage of inhibition of NAbs and the SARS-CoV-2 IgG II Quant (Abbott Laboratories, Chicago, IL, USA) and BioPlex 2200 SARS-CoV-2 IgG Panel (Bio-Rad, Hercules, CA, USA) immunoassays: rho = 0.87 (V1) and rho = 0.73 (V2) for anti-S1 assessed by Abbott assay; rho = 0.77 (V1) and rho = 0.72 (V2) for anti-S1, rho = 0.88 (V1) and rho = 0.82 (V2) for anti-RBD, and rho = 0.68 (V1) and rho = 0.60 (V2) for anti-S2 assessed by BioPlex assay (p < 0.001 for all). In conclusion, we found a strong correlation between this fast, user-friendly, mobile and bio-safe sVNT and the serological immunoassays.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (186)
This publication has 34 references indexed in Scilit:
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological ImmunoassayThe Journal of Applied Laboratory Medicine, 2020
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonThe Lancet Infectious Diseases, 2020
- COVID-19 and the Path to ImmunityJAMA, 2020
- Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?Signal Transduction and Targeted Therapy, 2020
- Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaquesScience, 2020
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, BrazilEmerging Infectious Diseases, 2019
- Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccinationVaccine, 2008
- Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human seraJournal of Virological Methods, 2005